These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 21631372)
21. Combined Oral Contraceptives As Victims of Drug Interactions. Li L; Yang X; Tran D; Seo SK; Lu Y Drug Metab Dispos; 2023 Jun; 51(6):718-732. PubMed ID: 36963837 [TBL] [Abstract][Full Text] [Related]
22. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785 [TBL] [Abstract][Full Text] [Related]
23. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Menendez JA; Oza BP; Colomer R; Lupu R Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863 [TBL] [Abstract][Full Text] [Related]
24. [Influence of progestins on adverse effects of oral contraceptives]. Wynn V Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210 [TBL] [Abstract][Full Text] [Related]
25. The use of newer progestins for contraception. Sitruk-Ware R; Nath A Contraception; 2010 Nov; 82(5):410-7. PubMed ID: 20933114 [TBL] [Abstract][Full Text] [Related]
26. [Cardiovascular risks of oral contraceptives: dose-response relationship]. Kelleher CC Contracept Fertil Sex (Paris); 1991 Apr; 19(4):285-8. PubMed ID: 12343220 [TBL] [Abstract][Full Text] [Related]
27. Current use of oral contraceptives and the risk of first-ever ischemic stroke: A meta-analysis of observational studies. Xu Z; Li Y; Tang S; Huang X; Chen T Thromb Res; 2015 Jul; 136(1):52-60. PubMed ID: 25936231 [TBL] [Abstract][Full Text] [Related]
28. [How to choose an oral contraceptive in 1984]. Rozenbaum H Contracept Fertil Sex (Paris); 1984 Nov; 12(11):1201-6. PubMed ID: 12266609 [TBL] [Abstract][Full Text] [Related]
30. Progestin type affects the increase of heparanase level and procoagulant activity mediated by the estrogen receptor. Treger S; Ackerman S; Kaplan V; Ghanem S; Nadir Y Hum Reprod; 2021 Jan; 36(1):61-69. PubMed ID: 33306105 [TBL] [Abstract][Full Text] [Related]
33. Oral contraceptives and the risk of cardiovascular disease. Med Lett Drugs Ther; 1983 Jul; 25(640):69-70. PubMed ID: 6865850 [TBL] [Abstract][Full Text] [Related]
34. Risk of venous thromboembolism with drospirenone in combined oral contraceptive products. Sehovic N; Smith KP Ann Pharmacother; 2010 May; 44(5):898-903. PubMed ID: 20371756 [TBL] [Abstract][Full Text] [Related]
35. Sex steroids and breast cancer prevention. Spicer DV; Pike MC J Natl Cancer Inst Monogr; 1994; (16):139-47. PubMed ID: 7999456 [TBL] [Abstract][Full Text] [Related]
36. [Oral contraception and liver function]. Bergsjo P Tidsskr Nor Laegeforen; 1973 Mar; 93(9):583-8. PubMed ID: 4759808 [No Abstract] [Full Text] [Related]
37. Clinical significance of the androgenicity of progestins in hormonal therapy in women. Linn ES Clin Ther; 1990; 12(5):447-55. PubMed ID: 2268868 [TBL] [Abstract][Full Text] [Related]
38. Present status of oral contraceptives: 1. effectiveness; basis for selection; side effects; metabolic changes. Kistner RW Drug Ther (NY); 1971 Dec; 1(12):14-29. PubMed ID: 12306285 [TBL] [Abstract][Full Text] [Related]
39. Combined hormonal contraception and venous thromboembolism. MartÃnez F; Avecilla A Eur J Contracept Reprod Health Care; 2007 Jun; 12(2):97-106. PubMed ID: 17559006 [TBL] [Abstract][Full Text] [Related]
40. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer. van Leeuwen FE Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]